GENEDRIVE PLC (GDR) — Full year results briefing

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the GENEDRIVE PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and could be submitted at any time via the Q and A tab situated on the right hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll, And then I'd like to hand you over to the management team from GENEDRIVE PLC. Gino, good afternoon, sir. Hi. Thanks, Lee. Afternoon, everyone, and welcome. Thank you for taking the time to join us today. I'm joined by our CFO, Russ Shaw. And what I'd like to take you through today is I'd just like to spend a bit time just reminding you or refreshing you on the unmet clinical need that we address with our products and the positioning of these products. The highlights from our FY '25, which ended in June 25, obviously, and progress we've made since then. I'll hand over to Russ to guide you through the FY '25 financials, and then I'll just spend a little bit of time discussing what we see as the outlook for the company. So just to take a step right up elevator elevator view, what GENEDRIVE does. So GENEDRIVE at a glance, we as a company provide rapid pharmacogenetic testing solutions, and I'll come into bit of detail about that. And that's specifically for emergency health care settings at the moment. We've got two CEIVD certified pharmacogenetic products that address significant unmet clinical needs in two very important areas. One of these is neonatology, where we address antibio...